Jazz Pharmaceuticals director awarded 1,605 RSUs

RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.

Jazz Pharmaceuticals plc director Norbert G. Riedel received a grant of 1,605 restricted stock units on August 5, 2026 under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each unit represents a contingent right to one ordinary share and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following the award, 8,629 ordinary shares were reported as beneficially owned by the NORBERT G. RIEDEL 2023 TRUST, and a separate indirect holding entry shows 10,630 ordinary shares held by trust.

Insider Trade Summary

Grant/Award: 1,605 shares

Grant/Award 2 txns

Insider RIEDEL NORBERT G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1, F2	1,605	$0.00	$0.00
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Ordinary Shares — 8,629 shares (Direct); Ordinary Shares — 10,630 shares (Indirect, by Trust)

Footnotes (2)

1. F1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.
2. F2. Shares beneficially owned by NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by the reporting person and his immediate family.

Key Figures

Restricted stock units granted: 1,605 units Vesting date: July 23, 2027 Trust beneficial ownership after grant: 8,629 shares +2 more

5 metrics

Restricted stock units granted 1,605 units Grant to director Norbert G. Riedel on August 5, 2026

Vesting date July 23, 2027 RSUs vest in full on this date subject to conditions

Trust beneficial ownership after grant 8,629 shares Ordinary shares beneficially owned by NORBERT G. RIEDEL 2023 TRUST

Indirect trust holdings reported 10,630 shares Ordinary shares held indirectly by trust after reported transactions

Transaction price per share $0.0000 Equity grant reported at zero cash price per share

Key Terms

restricted stock units, Non-Employee Directors Stock Award Plan, contingent right, beneficially owned

4 terms

restricted stock units financial

"These restricted stock units are granted pursuant to the Issuer's 2007 Amended..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Non-Employee Directors Stock Award Plan financial

"granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan"

contingent right financial

"Each restricted stock unit represents a contingent right to receive one ordinary share"

beneficially owned financial

"Shares beneficially owned by NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled..."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did director Norbert G. Riedel acquire in this Form 4 for JAZZ?

Director Norbert G. Riedel acquired 1,605 restricted stock units of Jazz Pharmaceuticals. The grant was made on August 5, 2026 under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan as equity compensation.

When do Norbert G. Riedel’s 1,605 RSUs in JAZZ vest?

The 1,605 restricted stock units will vest in full on July 23, 2027. Vesting is subject to Riedel’s continuous service and certain additional conditions, after which each unit converts into one ordinary share.

How many Jazz Pharmaceuticals shares are reported as beneficially owned after this grant?

After the reported grant, 8,629 ordinary shares are shown as beneficially owned by the NORBERT G. RIEDEL 2023 TRUST. This trust is owned and controlled by Riedel and his immediate family, according to the filing footnote.

What indirect holdings by trust are disclosed for JAZZ in this filing?

A separate holding entry reports 10,630 ordinary shares held indirectly "by Trust." This reflects additional trust-related ownership in Jazz Pharmaceuticals, distinct from the 8,629 shares also reported as beneficially owned by the 2023 trust.

Were Norbert G. Riedel’s JAZZ equity transactions under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative. The grant is reported as equity compensation under the non-employee directors stock award plan, not as a trade executed pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 05:34 PM Accepted by SEC EDGAR 08/07/2026 - 05:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIEDEL NORBERT G

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/05/2026		A(1)		1,605	A	$0.0	8,629(2)	D
Ordinary Shares								10,630	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.

2. Shares beneficially owned by NORBERT G. RIEDEL 2023 TRUST, an entity owned and controlled by the reporting person and his immediate family.

	By: /s/Paz Dizon, as attorney in fact For: Norbert G. Riedel	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)